摘要
目的比较胃癌术后单纯化疗与胃癌术后同步放化疗的疗效及不良反应。方法将57例胃癌术后患者随机分为单纯化疗组与同步放化疗组,单纯化疗组采用6个周期XP方案(希罗达2 000 mg/m2d1~14+顺铂60 mg/m2d1 q3w)。同步放化疗组(第一阶段:2个周期XP方案化疗、第二阶段:放疗+希罗达1 650 mg/m25w、第三阶段:2个周期XP方案化疗)。结果同步放化疗组28例患者术后1、2、3、5年生存率为75.0%、64.3%、57.1%、46.4%;单纯化疗组29例患者术后1、2、3、5年生存率为65.5%、51.7%、32.1%、21.4%,两组不良反应主要包括白细胞减少、血小板减少、贫血恶心、呕吐、腹泻、外周神经毒性及手足综合征,且以1、2度为主,同步放化疗组白细胞减少、恶心呕吐、手足综合征发生率高于单纯化疗组,但可耐受。结论胃癌术后同步放化疗组1、2、3、5年生存率高于单纯化疗,且3、5年生存率有统计学意义,不良反应可耐受。
Objective To compare the effects and adverse reactions of chemotherapy and three dimensional conformal radiotherapy( 3D-CRT) plus chemotherapy for postoperative patients on gastric cancer. Methods 57 patients with gastric cancer after surgery were randomly divided into chemotherapy group and 3D-CRT plus chemotherapy group. 29 cases of chemotherapy group received 6 cycles of XP( capecitabine 2 000 mg / m2 per day on days 1 to 14 and cisplatin 60 mg / m2 on day 1,repeated every 3 weeks) chemotherapy. 28 cases of 3D-CRT plus chemotherapy group received 2 cycles of XP followed by 45-Gy XRT( capecitabine 1 650 mg/m2 per day for 5 weeks) and 2 cycles of XP. Results 1-,2-,3-and 5-year survival rates of radiochemotherapy group was 75. 0% 、64. 3% 、57. 1% 、46. 4%. The chemotherapy group was 65. 5% 、51. 7% 、32. 1% 、21. 4%. Adverse reactions included decreased white cells,decreased platelet,anemia,nausea,vomiting,diarrhea,peripheral nerve toxicity and handfoot syndrome,and mainly were at grades 1、2. Decreased white cells,nausea,vomiting and hand-foot syndrome in radiochemotherapy group were significantly higher than those of the chemotherapy group,Those adverse reactions of radiochemotherapy were tolerable. Conclusion 1-,2-,3-and 5-year survival rates of radiochemotherapy group are higher than those of the chemotherapy group. The difference of 3 and 5-year survival rates are statistically significant. Adverse reactions of radiochemotherapy were tolerable.
出处
《实用癌症杂志》
2015年第8期1215-1217,共3页
The Practical Journal of Cancer
关键词
胃癌
希罗达
顺铂
放疗
化疗
放化疗
Cancer
Capecitabine
Cisplatin
Radiotherapy
Chemotherapy
Radiochemotherapy
